The results of scRNA-seq analysis showed that rAAV-P2 treatment can increase the proportion of CD4+, CD8+ T cells, and NK cells in the tumor (Fig. 4f, g), suggesting an increased lymphocyte infiltration in 4T1 tumors. Here, CD4 is linked to neoplasm.